Eradivir dosed the first patient in a Phase 2 influenza study of EV25 in Bangladesh.
JUL 7, 2026
Clinical-stage biotechnology company developing small-molecule therapies that recruit naturally occurring antibodies to target infected cells, viruses, and other diseased cells for immune-mediated clearance
Clinical-stage biotechnology company developing small-molecule therapies that recruit naturally occurring antibodies to target infected cells, viruses, and other diseased cells for immune-mediated clearance. Its BAiT platform is being applied to influenza, RSV, and other serious diseases; lead candidate EV25 is designed to treat early- and late-stage influenza infections.